Holen Sie sich die Stockscreener-App
132.75
0.70%
0.92
Vorhandelsmarkt:
135.00
2.25
+1.69%
Schlusskurs vom Vortag:
$131.83
Offen:
$132.52
24-Stunden-Volumen:
575.51K
Relative Volume:
0.49
Marktkapitalisierung:
$13.14B
Einnahmen:
$2.41B
Nettoeinkommen (Verlust:
$305.80M
KGV:
45.00
EPS:
2.95
Netto-Cashflow:
$492.20M
1W Leistung:
+1.15%
1M Leistung:
+4.90%
6M Leistung:
-9.55%
1J Leistung:
-8.62%
1-Tages-Spanne:
$132.22
$133.31
1-Wochen-Bereich:
$131.07
$135.70
52-Wochen-Spanne:
$84.23
$157.98
Neurocrine Biosciences Inc Stock (NBIX) Company Profile
Firmenname
Neurocrine Biosciences Inc
Sektor
Telefon
(858) 617-7600
Adresse
6027 EDGEWOOD BEND COURT, SAN DIEGO, CA
Vergleichen Sie NBIX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NBIX
Neurocrine Biosciences Inc
|
132.75 | 12.99B | 2.41B | 305.80M | 492.20M | 2.95 |
|
ZTS
Zoetis Inc
|
151.19 | 68.05B | 9.29B | 2.52B | 2.28B | 5.57 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.55 | 46.58B | 30.08B | 710.16M | 4.45B | 0.2182 |
|
HLN
Haleon Plc Adr
|
9.65 | 43.71B | 14.35B | 1.85B | 0 | 0.4023 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.29 | 18.40B | 16.54B | -1.64B | 749.00M | -1.45 |
|
UTHR
United Therapeutics Corp
|
297.89 | 13.23B | 2.99B | 1.21B | 1.13B | 25.06 |
Neurocrine Biosciences Inc Stock (NBIX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-21 | Eingeleitet | Truist | Buy |
| 2025-07-10 | Eingeleitet | Goldman | Buy |
| 2025-04-15 | Hochstufung | Needham | Hold → Buy |
| 2025-04-14 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2025-02-11 | Eingeleitet | Deutsche Bank | Hold |
| 2024-10-10 | Fortgesetzt | Raymond James | Outperform |
| 2024-08-29 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2024-04-24 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2023-12-13 | Fortgesetzt | Citigroup | Neutral |
| 2023-12-12 | Eingeleitet | Deutsche Bank | Buy |
| 2023-10-24 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2023-08-21 | Bestätigt | Mizuho | Neutral |
| 2023-07-24 | Hochstufung | SVB Securities | Market Perform → Outperform |
| 2023-07-06 | Hochstufung | BMO Capital Markets | Underperform → Market Perform |
| 2023-05-04 | Hochstufung | Guggenheim | Neutral → Buy |
| 2023-03-30 | Hochstufung | Canaccord Genuity | Hold → Buy |
| 2023-03-03 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2023-02-03 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2022-11-14 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2022-10-11 | Eingeleitet | UBS | Buy |
| 2022-09-26 | Eingeleitet | Wells Fargo | Equal Weight |
| 2022-06-06 | Fortgesetzt | Jefferies | Buy |
| 2022-03-03 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2022-02-25 | Hochstufung | Goldman | Neutral → Buy |
| 2022-01-18 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2021-11-19 | Eingeleitet | BMO Capital Markets | Underperform |
| 2021-11-17 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2021-10-14 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-09-23 | Fortgesetzt | Needham | Hold |
| 2021-08-06 | Herabstufung | Canaccord Genuity | Buy → Hold |
| 2021-05-18 | Fortgesetzt | Goldman | Neutral |
| 2021-05-06 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2021-02-02 | Eingeleitet | Raymond James | Outperform |
| 2020-09-30 | Eingeleitet | The Benchmark Company | Hold |
| 2020-08-04 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2020-06-29 | Herabstufung | Goldman | Buy → Neutral |
| 2020-06-09 | Eingeleitet | Wedbush | Outperform |
| 2020-03-06 | Eingeleitet | Citigroup | Buy |
| 2020-02-27 | Eingeleitet | Barclays | Equal Weight |
| 2020-02-24 | Eingeleitet | William Blair | Outperform |
| 2020-02-06 | Eingeleitet | Mizuho | Neutral |
| 2020-02-05 | Bestätigt | H.C. Wainwright | Buy |
| 2019-12-13 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2019-08-07 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2019-07-16 | Eingeleitet | Oppenheimer | Outperform |
| 2019-06-05 | Eingeleitet | Guggenheim | Neutral |
| 2019-05-21 | Eingeleitet | Credit Suisse | Outperform |
| 2019-04-22 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2019-04-12 | Eingeleitet | Evercore ISI | Outperform |
| 2019-02-06 | Bestätigt | BofA/Merrill | Buy |
| 2019-01-23 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2018-12-13 | Eingeleitet | Goldman | Buy |
| 2018-11-21 | Eingeleitet | Canaccord Genuity | Buy |
Alle ansehen
Neurocrine Biosciences Inc Aktie (NBIX) Neueste Nachrichten
What analysts say about Neurocrine Biosciences Inc. stockFree Investment Community - jammulinksnews.com
What drives Neurocrine Biosciences Inc. stock priceAccelerated investment success - Autocar Professional
Neurocrine Biosciences Inc. Stock Analysis and ForecastBreakthrough profits - Autocar Professional
Truist Securities Initiates Coverage of Neurocrine Biosciences (NBIX) with Buy Recommendation - MSN
Lobbying Update: $890,000 of NEUROCRINE BIOSCIENCES INC lobbying was just disclosed - Quiver Quantitative
Truist Securities initiates Neurocrine Bio stock with Buy rating on Crenessity potential - Investing.com Canada
Neurocrine Biosciences (NASDAQ:NBIX) Now Covered by Truist Financial - MarketBeat
Is Neurocrine Biosciences Inc. a good long term investmentExplosive capital gains - Autocar Professional
Daily Turnover | The turnover of Neurocrine Biosciences on 7/18 was $100.31 Million, Ranking 820 - AInvest
Is Neurocrine Biosciences, Inc.'s (NASDAQ:NBIX) Recent Stock Performance Influenced By Its Fundamentals In Any Way? - simplywall.st
Neurocrine Biosciences’ NBI-921352 Study: A Potential Game-Changer for SCN8A-DEE Treatment - TipRanks
Lobbying Update: $80,000 of NEUROCRINE BIOSCIENCES INC. lobbying was just disclosed - Nasdaq
Voyager Adds Fourth Wholly-Owned Alzheimer’s Disease Program to Pipeline, Complementing Existing Tau and Amyloid Assets with New APOE Approach - GlobeNewswire Inc.
Neurocrine reports positive results from Crenessity trial - MSN
Neurocrine Biosciences shares rise 2.09% after-hours after presenting new analysis on CAH treatment. - AInvest
Neurocrine shares new one-year data from trial of Crenessity for CAH - Yahoo Finance
Groundbreaking AI Research Exposes Lifelong Treatment Challenges for Rare CAH Patients - Stock Titan
Neurocrine shares registry data showing CAH treatment challenges - StreetInsider
Neurocrine Biosciences Presents New Analysis of CAHtalog® Registry Showing Most Patients with Classic Congenital Adrenal Hyperplasia Experienced High Glucocorticoid Exposure, Suboptimal Disease Control or Both at ENDO 2025 - PR Newswire
New weight reduction data for Crenessity presented by Neurocrine - The Pharma Letter
Wedbush Raises Price Target on Neurocrine Biosciences to $137 From $130, Keeps Outperform Rating - MarketScreener
What makes Neurocrine Biosciences Inc. stock price move sharplyMassive Upside Selection - beatles.ru
NBIX : Phase 3 Study Shows CRENESSITY Improves Weight-Related Outcomes In Adrenal Disorder Patients - Nasdaq
Endometriosis Market to Reach New Heights in Growth by 2034, - openPR.com
Neurocrine Biosciences CRENESSITY Shows Clinically Meaningful Weight Loss And Insulin Resistance Improvement In Adults And Children With CAH In Phase 3 Trials, Presented At ENDO 2025 - 富途牛牛
Neurocrine presents one-year data showing weight improvements with CRENESSITY - StreetInsider
Neurocrine Biosciences Presented One-Year Data from Phase 3 CAHtalyst™ Studies Showing Improvements in Weight-Related Effects of Glucocorticoid Treatment at the 2025 Endocrine Society's Annual Meeting - Eastern Progress
Neurocrine presents one-year CRENESSITY data at ENDO 2025 conference - StreetInsider
Neurocrine Biosciences Reports Positive 1-year Data Of Crenessity In Adults With CAH At ENDO 2025 - Nasdaq
Neurocrine Biosciences: CRENESSITY's Breakthrough in CAH Positions NBIX for Sustained Growth - AInvest
Neurocrine reports positive results from Crenessity trial (NBIX) - Seeking Alpha
Neurocrine reports positive one-year data for CAH treatment By Investing.com - Investing.com India
Neurocrine presents one-year data from study of Crenessity - TipRanks
CRENESSITY's Groundbreaking CAH Data Positions Neurocrine Biosciences for Dominance in a High-Impact Market - AInvest
Neurocrine reports positive one-year data for CAH treatment - Investing.com
New Clinical Data: CRENESSITY Achieves Breakthrough 30% Steroid Reduction in Adult CAH Treatment - Stock Titan
Neurocrine Biosciences (NASDAQ:NBIX) Given New $174.00 Price Target at UBS Group - MarketBeat
Neurocrine Biosciences (NBIX) CSO Onyia sells $7.8m in stock By Investing.com - Investing.com Canada
Neurocrine Biosciences (NBIX) CSO Onyia sells $7.8m in stock - Investing.com Australia
Neurocrine Biosciences: Insider Selling StormShould Investors Be Alarmed? - AInvest
Neurocrine Biosciences Insider Unloads $7.8mln in Shares According to Recent SEC Filing - AInvest
Finanzdaten der Neurocrine Biosciences Inc-Aktie (NBIX)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.63%
0.96%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):